copper peptide ghk-cu 1:1 Tripeptide-1 GHK-Cu Copper Tripeptide-1 | Research

While it is not a standalone cancer treatment, its ability to support immune competence has made it an area of significant scientific interest

Preclinical studies report minimal adverse effects at standard research doses, but peptide purity, correct amino acid sequencing, and sterile reconstitution are critical contaminated or incorrectly synthesized compounds carry infection risk and unpredictable biological effects

Community-reported doses (commonly 5-20 mg/day in forum and vendor sources) are not derived from human pharmacokinetic data and are not guidance

USADA was created as the result of recommendations made by the United States Olympic & Paralympic Committees Select Task Force on Externalization

The peptide was originally developed by researchers seeking to isolate the lipolytic effects of growth hormone from its other physiological actions